Universal, off-the-shelf cell therapy

Allocetra™ is an innovative immunotherapy that is being developed to reprogram macrophages,
which were negatively reprogrammed by certain diseases out of their homeostatic state.



Mononuclear cells collected
from healthy donors


Cells modification


Modified through a proprietary
process to express “eat me”
signal (PtdSer) on their surface,
while maintaining an intact membrane




Triggering engulfment into
macrophages via binding to BAI,
TIM4, and stabilin 2, annexin V

allocetra Activated macrophage

allocetra Homeostatic macrophage

Clinical focus

Our clinical development programs focus on treating sepsis and osteoarthritis. Our most advanced product candidate, Allocetra™, has demonstrated positive safety, tolerability and efficacy in several clinical trials. In addition to our ongoing late-stage clinical trial in sepsis, we plan on initiating clinical trials of Allocetra™ in osteoarthritis patients during 2024.

Clinical experience
Extensive pre-clinical data
Clinical experience
Rich pipeline of registration studies targeting conditional marketing approval
Clinical experience
3 primary indications

Recent Publications